Slayback Pharma and the Everstone Group have struck a deal that will see Everstone invest up to $50m in the US-based complex generics specialist.
Complex generics specialist Slayback Pharma has announced a deal with private equity firm the Everstone Group that will see Everstone invest “up to $50m in Series B funding” in the New Jersey-based company.
As part of the deal, Everstone managing directors Arjun Oberoi and Puncham Mukim will join Slayback’s board of directors.
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
